The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Suppression of Rev3, the catalytic subunit of Polζ, sensitizes drug-resistant lung tumors to chemotherapy
Open accessAbstract
Platinum-based chemotherapeutic drugs are front-line therapies for the treatment of non-small cell lung cancer. However, intrinsic drug resistance limits the clinical efficacy of these agents. Recent evidence suggests that loss of the translesion polymerase, Polζ, can sensitize tumor cell lines to cisplatin, although the relevance of these findings to the treatment of chemoresistant tumors in vivo has remained unclear. Here, we describe a tumor transplantation approach that enables the rapid introduction of defined genetic lesions into a preclinical model of lung adenocarcinoma. Using this approach, we examined the effect of impaired translesion DNA synthesis on cisplatin response in aggressive late-stage lung cancers. In the presence of reduced levels of Rev3, an essential component of Polζ, tumors exhibited pronounced sensitivity to cisplatin, leading to a significant extension in overall survival of treated recipient mice. Additionally, treated Rev3-deficient cells exhibited reduced cisplatin-induced mutation, a process that has been implicated in the induction of secondary malignancies following chemotherapy. Taken together, our data illustrate the potential of Rev3 inhibition as an adjuvant therapy for the treatment of chemoresistant malignancies, and highlight the utility of rapid transplantation methodologies for evaluating mechanisms of chemotherapeutic resistance in preclinical settings.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“targeting the translesion synthesis polymerase REV3, which restores cisplatin sensitivity to lung tumors [82]”
From Hereditary Breast Cancer and the BRCA1-Associated FANCJ/BACH1/BRIP1 (2011) · cites this paper as [82]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Friedberg, E. C., Walker, G. C., Siede, W., Wood, R. D., Schultz, R. A., & Ellenberger, T. (2005) · doi:10.1128/9781555816704 · Cited by 5,683
Self-citationSpecific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198
Direct Cellular Responses to Platinum-Induced DNA Damage
Jung, Y., & Lippard, S. J. (2007) · Chemical Reviews · doi:10.1021/cr068207j · Cited by 1,412
The mighty mouse: genetically engineered mouse models in cancer drug development
Sharpless, N. E., & DePinho, R. A. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2110 · Cited by 674
Eukaryotic Translesion Polymerases and Their Roles and Regulation in DNA Damage Tolerance
Waters, L. S., Minesinger, B. K., Wiltrout, M. E., D'Souza, S., Woodruff, R. V., & Walker, G. C. (2009) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00034-08 · Cited by 591
Self-citationProbing tumor phenotypes using stable and regulated synthetic microRNA precursors
Dickins, R. A., Hemann, M. T., Zilfou, J. T., Simpson, D. R., Ibarra, I., Hannon, G. J., & Lowe, S. W. (2005) · Nature Genetics · doi:10.1038/ng1651 · Cited by 522
Self-citationMechanism of Replication-Coupled DNA Interstrand Crosslink Repair
Räschle, M., Knipscheer, P., Enoiu, M., Angelov, T., Sun, J., Griffith, J. D., Ellenberger, T., Schärer, O. D., & Walter, J. C. (2008) · Cell · doi:10.1016/j.cell.2008.08.030 · Cited by 507
Fuertes, M., Castilla, J., Alonso, C., & Pérez, J. (2003) · Current Medicinal Chemistry · doi:10.2174/0929867033368484 · Cited by 432
An oncogenic KRAS2 expression signature identified by cross-species gene-expression analysis.
Sweet-Cordero, A., Mukherjee, S., Subramanian, A., You, H., Roix, J. J., Ladd-Acosta, C., Mesirov, J., Golub, T. R., & Jacks, T. (2005) · Nature Genetics · doi:10.1038/ng1490 · Cited by 414
Self-citation
Cited by
Sorted by citations
Whole genomes redefine the mutational landscape of pancreatic cancer
Initiative, A. P. C. G., Waddell, N., Pajic, M., Patch, A.-M., Chang, D. K., Kassahn, K. S., Bailey, P., Johns, A. L., Miller, D., Nones, K., et al. (2015) · Nature · doi:10.1038/nature14169 · Cited by 2,642
Mechanisms of DNA damage, repair, and mutagenesis
Chatterjee, N., & Walker, G. C. (2017) · Environmental and Molecular Mutagenesis · doi:10.1002/em.22087 · Cited by 2,039
“Interestingly, the TLS polymerases, REV1 and REV3, were also implicated in the development of chemore- sistance in human cells and mice models, opening the possi- bility for a whole new class of promising chemotherapeutic drugs [Doles et al., 2010; Xie et al., 2010; Xu et al., 2013].”
Self-citationCancer nanomedicine: from targeted delivery to combination therapy
Xu, X., Ho, W., Zhang, X., Bertrand, N., & Farokhzad, O. (2015) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2015.01.001 · Cited by 693
Y-family DNA polymerases and their role in tolerance of cellular DNA damage
Sale, J. E., Lehmann, A. R., & Woodgate, R. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3289 · Cited by 665
The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance
Bouwman, P., & Jonkers, J. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3342 · Cited by 615
Lange, S. S., Takata, K.-I., & Wood, R. D. (2011) · Nature Reviews Cancer · doi:10.1038/nrc2998 · Cited by 615
Regulation of DNA cross-link repair by the Fanconi anemia/BRCA pathwayPreprint
Kim, H., & D’Andrea, A. D. (2012) · Genes & Development · doi:10.1101/gad.195248.112 · Cited by 534
Advances in Toxicological Research of the Anticancer Drug Cisplatin
Qi, L., Luo, Q., Zhang, Y., Jia, F., Zhao, Y., & Wang, F. (2019) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.9b00204 · Cited by 457
Regulation of PCNA–protein interactions for genome stability
Mailand, N., Gibbs‐Seymour, I., & Bekker‐Jensen, S. (2013) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3562 · Cited by 395
Xu, X., Xie, K., Zhang, X.-Q., Pridgen, E. M., Park, G. Y., Cui, D. S., Shi, J., Wu, J., Kantoff, P. W., Lippard, S. J., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1303958110 · Cited by 340
Self-citationTranslesion DNA Synthesis and Mutagenesis in Eukaryotes
Sale, J. E. (2013) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a012708 · Cited by 282
Mutational signatures are jointly shaped by DNA damage and repair
Volkova, N. V., Meier, B., González‐Huici, V., Bertolini, S., González, S., Vöhringer, H. S., Abascal, F., Martincorena, I., Campbell, P. J., Gartner, A., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15912-7 · Cited by 227
Error-prone translesion synthesis mediates acquired chemoresistance
Xie, K., Doles, J. D., Hemann, M. T., & Walker, G. C. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1011412107 · Cited by 228
Self-citationBcl-2 Antiapoptotic Family Proteins and Chemoresistance in Cancer
Maji, S., Panda, S., Samal, S. K., Shriwas, O., Rath, R., Pellecchia, M., Emdad, L., Das, S. K., Fisher, P. B., & Dash, R. (2017) · Advances in cancer research · doi:10.1016/bs.acr.2017.11.001 · Cited by 216
DNA damage tolerance: a double-edged sword guarding the genome.
Ghosal, G., & Chen, J. (2013) · PubMed · doi:10.3978/j.issn.2218-676x.2013.04.01 · Cited by 215
A Small Molecule Targeting Mutagenic Translesion Synthesis Improves Chemotherapy
Wojtaszek, J. L., Chatterjee, N., Najeeb, J., Ramos, A., Lee, M., Bian, K., Xue, J. Y., Fenton, B. A., Park, H., Li, D., et al. (2019) · Cell · doi:10.1016/j.cell.2019.05.028 · Cited by 194
Self-citationSrivastava, A. K., Han, C., Zhao, R., Cui, T., Dai, Y., Mao, C., Zhao, W., Zhang, X., Yu, J., & Wang, Q.-E. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1421365112 · Cited by 188
Lee, Y., Gregory, M., & Yang, W. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1324001111 · Cited by 167
Resistance to therapy in BRCA2 mutant cells due to loss of the nucleosome remodeling factor CHD4Preprint
Guillemette, S., Serra, R. W., Peng, M., Hayes, J. A., Konstantinopoulos, P. A., Green, M. R., & Cantor, S. B. (2015) · Genes & Development · doi:10.1101/gad.256214.114 · Cited by 157
New challenges in the use of nanomedicine in cancer therapy
Rasool, M., Malik, A., Waquar, S., Arooj, M., Zahid, S., Asif, M., Shaheen, S., Hussain, A., Ullah, H., & Gan, S. H. (2021) · Bioengineered · doi:10.1080/21655979.2021.2012907 · Cited by 137
Leveraging the replication stress response to optimize cancer therapy
Cybulla, E., & Vindigni, A. (2022) · Nature reviews. Cancer · doi:10.1038/s41568-022-00518-6 · Cited by 144
Response and Resistance to NF-κB Inhibitors in Mouse Models of Lung Adenocarcinoma
Xue, W., Meylan, E., Oliver, T. G., Feldser, D. M., Winslow, M. M., Bronson, R. T., & Jacks, T. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0073 · Cited by 131
Self-citationMulti-drug delivery nanocarriers for combination therapy
Gadde, S. (2015) · MedChemComm · doi:10.1039/c5md00365b · Cited by 127
Kim, B., Sun, S., Varner, J. A., Howell, S. B., Ruoslahti, E. I., & Sailor, M. J. (2019) · Advanced Materials · doi:10.1002/adma.201902952 · Cited by 122
Nayak, S. U., Calvo, J. A., Cong, K., Peng, M., Berthiaume, E. A., Jackson, J., Zaino, A. M., Vindigni, A., Hadden, M. K., & Cantor, S. B. (2020) · Science Advances · doi:10.1126/sciadv.aaz7808 · Cited by 119
DNA polymerase ζ in DNA replication and repair
Martin, S. K., & Wood, R. D. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz705 · Cited by 119
DNA damage repair and tolerance: a role in chemotherapeutic drug resistance
Salehan, M. R., & Morse, H. (2013) · British Journal of Biomedical Science · doi:10.1080/09674845.2013.11669927 · Cited by 112
Wojtaszek, J. L., Lee, C., D’Souza, S., Minesinger, B. K., Kim, H., D’Andrea, A. D., Walker, G. C., & Zhou, P. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.394841 · Cited by 115
Self-citationHereditary Breast Cancer and the BRCA1-Associated FANCJ/BACH1/BRIP1
Cantor, S. B., & Guillemette, S. (2011) · Future Oncology · doi:10.2217/fon.10.191 · Cited by 106
“Furthermore, if an unregulated FANCJ contributes to unscheduled DNA damage tolerance, targeting FANCJ could prevent chemoresistance akin to targeting the trans lesion synthesis polymerase REV3, which restores cisplatin sensitivity to lung tumors [82].”
Structural Basis of Recruitment of DNA Polymerase ζ by Interaction between REV1 and REV7 Proteins
Kikuchi, S., Hara, K., Shimizu, T., Sato, M., & Hashimoto, H. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.396838 · Cited by 103
Versatile in vivo regulation of tumor phenotypes by dCas9-mediated transcriptional perturbation
Braun, C. J., Bruno, P. M., Horlbeck, M. A., Gilbert, L. A., Weissman, J. S., & Hemann, M. T. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1600582113 · Cited by 104
Self-citationShe, R., Chakravarty, A. K., Layton, C. J., Chircus, L. M., Andreasson, J. O. L., Damaraju, N., McMahon, P. L., Buenrostro, J. D., Jarosz, D. F., & Greenleaf, W. J. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1618370114 · Cited by 97
Mechanisms of DNA Damage Tolerance: Post-Translational Regulation of PCNA
Leung, W., Baxley, R. M., Moldovan, G., & Bielinsky, A. (2018) · Genes · doi:10.3390/genes10010010 · Cited by 100
Cannell, I. G., Merrick, K. A., Morandell, S., Zhu, C., Braun, C. J., Grant, R. A., Cameron, E. R., Tsao, M., Hemann, M. T., & Yaffe, M. B. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.09.009 · Cited by 91
Self-citationCompetition, collaboration and coordination – determining how cells bypass DNA damage
Sale, J. E. (2012) · Journal of Cell Science · doi:10.1242/jcs.094748 · Cited by 96
Can Cisplatin Therapy Be Improved? Pathways That Can Be Targeted
Ali, R., Aouida, M., Sulaiman, A. A., Madhusudan, S., & Ramotar, D. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23137241 · Cited by 92
Inhibition of mutagenic translesion synthesis: A possible strategy for improving chemotherapy?
Yamanaka, K., Chatterjee, N., Hemann, M. T., & Walker, G. C. (2017) · PLOS Genetics · doi:10.1371/journal.pgen.1006842 · Cited by 87
Self-citationLuo, H., Chen, Z., Wang, S., Zhang, R., Qiu, W., Zhao, L., Peng, C., Xu, R., Chen, W., Wang, H., et al. (2015) · Brain · doi:10.1093/brain/awv287 · Cited by 84
Biomaterials in siRNA Delivery: A Comprehensive Review
Ho, W., Zhang, X., & Xu, X. (2016) · Advanced Healthcare Materials · doi:10.1002/adhm.201600418 · Cited by 85
DNA damage response regulation by microRNAs as a therapeutic target in cancer
Majidinia, M., & Yousefi, B. (2016) · DNA repair · doi:10.1016/j.dnarep.2016.09.003 · Cited by 84
Yamada, M., Watanabe, K., Mistrík, M., Veselá, E., Protivankova, I., Mailand, N., Lee, M., Masai, H., Lukas, J., & Bartek, J. (2013) · Genes & Development · doi:10.1101/gad.224568.113 · Cited by 81
Multifaceted Recognition of Vertebrate Rev1 by Translesion Polymerases ζ and κ
Wojtaszek, J. L., Liu, J., D’Souza, S., Wang, S., Xue, J. Y., Walker, G. C., & Zhou, P. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.380998 · Cited by 82
Self-citationHaynes, B. M., Saadat, N., Myung, B., & Shekhar, M. P. V. (2014) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2014.11.005 · Cited by 77
Pozhidaeva, A., Pustovalova, Y., D’Souza, S., Bezsonova, I., Walker, G. C., & Korzhnev, D. M. (2012) · Biochemistry · doi:10.1021/bi300566z · Cited by 80
Self-citationMultifunctional platinum‐based nanoparticles for biomedical applications
Cheng, Q., & Liu, Y. (2016) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1410 · Cited by 79
Roles of trans-lesion synthesis (TLS) DNA polymerases in tumorigenesis and cancer therapy
Anand, J. R., Chiou, L. F., Sciandra, C. A., Zhang, X., Hong, J., Wu, D., Zhou, P., & Vaziri, C. (2023) · NAR Cancer · doi:10.1093/narcan/zcad005 · Cited by 75
Involvement of translesion synthesis DNA polymerases in DNA interstrand crosslink repair
Roy, U., & Schärer, O. D. (2016) · DNA repair · doi:10.1016/j.dnarep.2016.05.004 · Cited by 73
Nanoparticle-based drug delivery systems with platinum drugs for overcoming cancer drug resistance
Xie, P., Wang, Y., Wei, D., Zhang, L., Zhang, B., Xiao, H., Song, H., & Mao, X. (2021) · Journal of Materials Chemistry B · doi:10.1039/d1tb00753j · Cited by 71
Peng, C., Chen, Z., Wang, S., Wang, H., Qiu, W., Zhao, L., Xu, R., Luo, H., Chen, D., Chen, D., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1884 · Cited by 73
Sharma, S., Helchowski, C. M., & Canman, C. E. (2012) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2012.11.002 · Cited by 71
Structure and mechanism of B-family DNA polymerase ζ specialized for translesion DNA synthesis
Malik, R., Kopylov, M., Gómez-Llorente, Y., Jain, R., Johnson, R. E., Prakash, L., Prakash, S., Ubarretxena‐Belandia, I., & Aggarwal, A. K. (2020) · Nature Structural & Molecular Biology · doi:10.1038/s41594-020-0476-7 · Cited by 67
Breaking the DNA damage response to improve cervical cancer treatment
Wieringa, H. W., van der Zee, A. G. J., de Vries, E. G. E., & van Vugt, M. A. T. M. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.11.008 · Cited by 66
DNA Polymerase ζ Is a Major Determinant of Resistance to Platinum-Based Chemotherapeutic Agents
Sharma, S., Shah, N. A., Joiner, A. M., Roberts, K. H., & Canman, C. E. (2012) · Molecular Pharmacology · doi:10.1124/mol.111.076828 · Cited by 65
Ziv, O., Zeisel, A., Mirlas-Neisberg, N., Swain, U., Nevo, R., Ben-Chetrit, N., Martelli, M. P., Rossi, R., Schiesser, S., Canman, C. E., et al. (2014) · Nature Communications · doi:10.1038/ncomms6437 · Cited by 59
Translesion DNA synthesis in the context of cancer research
Knobel, P. A., & Marti, T. M. (2011) · Cancer Cell International · doi:10.1186/1475-2867-11-39 · Cited by 64
Human REV3 DNA Polymerase Zeta Localizes to Mitochondria and Protects the Mitochondrial Genome
Singh, B., Li, X., Owens, K. M., Vanniarajan, A., Liang, P., & Singh, K. K. (2015) · PLoS ONE · doi:10.1371/journal.pone.0140409 · Cited by 62
Targeting the Translesion Synthesis Pathway for the Development of Anti-Cancer Chemotherapeutics
Korzhnev, D. M., & Hadden, M. K. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00596 · Cited by 58
Suppression of REV 7 enhances cisplatin sensitivity in ovarian clear cell carcinoma cells
Niimi, K., Murakumo, Y., Watanabe, N., Kato, T., Mii, S., Enomoto, A., Asai, M., Asai, N., Yamamoto, E., Kajiyama, H., et al. (2014) · Cancer Science · doi:10.1111/cas.12390 · Cited by 56
Inhibition of REV3 Expression Induces Persistent DNA Damage and Growth Arrest in Cancer Cells
Knobel, P. A., Kotov, I. N., Felley‐Bosco, E., Stahel, R. A., & Marti, T. M. (2011) · Neoplasia · doi:10.1593/neo.11828 · Cited by 59
Mechanisms of Post-Replication DNA Repair
Gao, Y., Mutter‐Rottmayer, E., Zlatanou, A., Vaziri, C., & Yang, Y. (2017) · Genes · doi:10.3390/genes8020064 · Cited by 58
Chatterjee, N., Whitman, M. A., Harris, C. A., Min, S. M., Jonas, O. H., Lien, E. C., Luengo, A., Heiden, M. G. V., Hong, J., Zhou, P., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2016064117 · Cited by 55
Self-citationREV1 and DNA polymerase zeta in DNA interstrand crosslink repair
Sharma, S., & Canman, C. E. (2012) · Environmental and Molecular Mutagenesis · doi:10.1002/em.21736 · Cited by 56
Han, B., Gao, G., Wu, W., Gao, Z., Zhao, X., Li, L., Qiao, R., Chen, H., Wei, Q., Wu, J., et al. (2010) · Lung Cancer · doi:10.1016/j.lungcan.2010.09.001 · Cited by 54
Sail, V., Rizzo, A. A., Chatterjee, N., Dash, R. C., Ozen, Z., Walker, G. C., Korzhnev, D. M., & Hadden, M. K. (2017) · ACS Chemical Biology · doi:10.1021/acschembio.6b01144 · Cited by 52
Self-citationA PolH Transcript with a Short 3′UTR Enhances PolH Expression and Mediates Cisplatin Resistance
Zhang, J., Sun, W., Ren, C., Kong, X., Yan, W., & Chen, X. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3928 · Cited by 53
Ancient genes establish stress-induced mutation as a hallmark of cancer
Cisneros, L. H., Bussey, K. J., Orr, A. J., Miočević, M., Lineweaver, C. H., & Davies, P. C. W. (2017) · PLoS ONE · doi:10.1371/journal.pone.0176258 · Cited by 49
Yoon, J.-H., Park, J., Conde, J., Wakamiya, M., Prakash, L., & Prakash, S. (2015) · Genes & Development · doi:10.1101/gad.272229.115 · Cited by 47
REV3L, a Promising Target in Regulating the Chemosensitivity of Cervical Cancer Cells
Yang, L., Shi, T., Liu, F., Ren, C., Wang, Z., Li, Y.-Y., Tu, X., Yang, G. S., & Cheng, X. (2015) · PLoS ONE · doi:10.1371/journal.pone.0120334 · Cited by 46
Targeting the microRNA-regulating DNA damage/repair pathways in cancer
Bottai, G., Pasculli, B., Călin, G. A., & Santarpia, L. (2014) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2014.950650 · Cited by 45
Structural insights into the assembly of human translesion polymerase complexes
Xie, W., Yang, X., Xu, M., & Jiang, T. (2012) · Protein & Cell · doi:10.1007/s13238-012-2102-x · Cited by 45
Translesion synthesis ofO4-alkylthymidine lesions in human cells
Wu, J., Li, L., Wang, P., You, C., Williams, N. L., & Wang, Y. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw662 · Cited by 43
Identification of the first small-molecule inhibitor of the REV7 DNA repair protein interaction
Actis, M. L., Ambaye, N. D., Evison, B. J., Shao, Y., Vanarotti, M., Inoue, A., McDonald, E. T., Kikuchi, S., Heath, R., Hara, K., et al. (2016) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2016.07.026 · Cited by 42
Kochenova, O. V., Daee, D. L., Mertz, T. M., & Shcherbakova, P. V. (2015) · PLoS Genetics · doi:10.1371/journal.pgen.1005110 · Cited by 45
Overcoming multiple drug resistance in lung cancer using siRNA targeted therapy
Naghizadeh, S., Mohammadi, A., Baradaran, B., & Mansoori, B. (2019) · Gene · doi:10.1016/j.gene.2019.143972 · Cited by 41
Kong, Y. W., Dreaden, E. C., Morandell, S., Zhou, W., Dhara, S. S., Sriram, G., Lam, F. C., Patterson, J. C., Quadir, M., Dinh, A., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17958-z · Cited by 42
Self-citationTranslesion synthesis inhibitors as a new class of cancer chemotherapeutics
Patel, S. M., Dash, R. C., & Hadden, M. K. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.1850692 · Cited by 39
Drug resistance in the mouse cancer clinic
Rottenberg, S., & Borst, P. (2012) · Drug Resistance Updates · doi:10.1016/j.drup.2012.01.001 · Cited by 40
Dual role for mammalian DNA polymerase ζ in maintaining genome stability and proliferative responses
Lange, S. S., Bedford, E., Reh, S., Wittschieben, J. P., Carbajal, S., Kusewitt, D. F., DiGiovanni, J., & Wood, R. D. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1217425110 · Cited by 39
The Rev1-Polζ translesion synthesis mutasome: Structure, interactions and inhibition
Rizzo, A. A., & Korzhnev, D. M. (2019) · The Enzymes · doi:10.1016/bs.enz.2019.07.001 · Cited by 40
DNA polymerase eta: A potential pharmacological target for cancer therapy
Saha, P., Mandal, T., Talukdar, A. D., Kumar, D., Kumar, S., Tripathi, P. P., Wang, Q., & Srivastava, A. K. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.30155 · Cited by 41
Chun, A. C. S., Kok, K., & Jin, D. (2013) · Cell Cycle · doi:10.4161/cc.23214 · Cited by 39
Multifunctional Role of Astrocyte Elevated Gene-1 (AEG-1) in Cancer: Focus on Drug Resistance
Manna, D., & Sarkar, D. (2021) · Cancers · doi:10.3390/cancers13081792 · Cited by 38
Biomedical,clinical and environmental applications of platinum-based nanohybrids: An updated review
Yerpude, S. T., Potbhare, A. K., Bhilkar, P. R., Rai, A. R., Singh, R. P., Abdala, A. A., Adhikari, R., Sharma, R., & Chaudhary, R. G. (2023) · Environmental Research · doi:10.1016/j.envres.2023.116148 · Cited by 39
Barnes, R. P., Tsao, W.-C., Moldovan, G., & Eckert, K. A. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-3931 · Cited by 38
Germline genome protection: implications for gamete quality and germ cell tumorigenesis
Bloom, J. C., Loehr, A. R., Schimenti, J. C., & Weiss, R. S. (2019) · Andrology · doi:10.1111/andr.12651 · Cited by 38
Targeting translesion synthesis (TLS) to expose replication gaps, a unique cancer vulnerability
Nayak, S. U., Calvo, J. A., & Cantor, S. B. (2021) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2021.1864321 · Cited by 37
Lesion bypass by S. cerevisiae Pol ζ alone
Stone, J. E., Kumar, D., Binz, S. K., Inase, A., Iwai, S., Chabes, A., Burgers, P., & Kunkel, T. A. (2011) · DNA repair · doi:10.1016/j.dnarep.2011.04.032 · Cited by 37
RAD18 mediates resistance to ionizing radiation in human glioma cells
Xie, C., Wang, H., Cheng, H., Li, J., Wang, Z., & Wu, Y. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.02.003 · Cited by 36
Wu, B., Wang, H., Zhang, L., Sun, C., Li, H., Jiang, C., & Liu, X. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.01.016 · Cited by 35
Chromatin Regulates Genome Targeting with Cisplatin
Zacharioudakis, E., Agarwal, P., Bartoli, A., Abell, N. S., Kunalingam, L., Bergoglio, V., Xhemalçe, B., Miller, K. M., & Rodriguez, R. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201701144 · Cited by 35
Lange, S. S., Tomida, J., Boulware, K. S., Bhetawal, S., & Wood, R. D. (2016) · PLoS Genetics · doi:10.1371/journal.pgen.1005759 · Cited by 34
The Regulation of DNA Damage Tolerance by Ubiquitin and Ubiquitin-Like Modifiers
Cipolla, L., Maffia, A., Bertoletti, F., & Sabbioneda, S. (2016) · Frontiers in Genetics · doi:10.3389/fgene.2016.00105 · Cited by 38
Thrall, E. S., Kath, J. E., Chang, S., & Loparo, J. J. (2017) · Nature Communications · doi:10.1038/s41467-017-02333-2 · Cited by 32
Vassel, F.-M., Bian, K., Walker, G. C., & Hemann, M. T. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2016067117 · Cited by 32
Self-citationStanzione, M., Zhong, J., Wong, E., LaSalle, T. J., Wise, J. F., Simoneau, A., Myers, D. T., Phat, S., Sade-Feldman, M., Lawrence, M. S., et al. (2022) · Science Advances · doi:10.1126/sciadv.abn1229 · Cited by 32
Roy, U., Mukherjee, S., Sharma, A., Frank, E. G., & Schärer, O. D. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw485 · Cited by 31
Kim, J. Y., Kim, S.-K., Kang, D., & Moon, M. H. (2012) · Analytical Chemistry · doi:10.1021/ac300772w · Cited by 30
Can pharmacogenetics explain efficacy and safety of cisplatin pharmacotherapy?
Roco, Á., Cayún, J. P., Castillo, S. C., Stojanova, J., & Quiñones, L. A. (2014) · Frontiers in Genetics · doi:10.3389/fgene.2014.00391 · Cited by 30
Sakurai, Y., Ichinoe, M., Yoshida, K., Nakazato, Y., Saito, S., Satoh, M., Nakada, N., Sanoyama, I., Umezawa, A., Numata, Y., et al. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.06.001 · Cited by 31
Replication Fork Remodeling and Therapy Escape in DNA Damage Response-Deficient Cancers
Liptay, M., Barbosa, J. S., & Rottenberg, S. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00670 · Cited by 30
Metadata
- Authors
- Doles, J., Oliver, T. G., Cameron, E. R., Hsu, G., Jacks, T., Walker, G. C., & Hemann, M. T.
- Affiliations
- Koch Institute for Integrative Cancer Research At MIT (US)
- Howard Hughes Medical Institute (US)
- Department of Biology, and
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2010-11-10
- Volume
- 107
- Issue
- 48
- Pages
- 20786-20791
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC2996428
- OpenAlex
- W2012012836
- Cited by
- 190
- References
- 40
- Citations by year
- 2026: 5 · 2025: 3 · 2024: 5 · 2023: 8 · 2022: 6 · 2021: 11 · 2020: 26 · 2019: 14 · 2018: 5 · 2017: 16 · 2016: 17 · 2015: 18 · 2014: 16 · 2013: 13 · 2012: 18
- FWCI
- 5.21
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc)
- Funders
- Howard Hughes Medical Institute
- Massachusetts Institute of Technology (P30-CA14051)
- Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology (P30-CA14051, Grant P30-CA14051)
- National Institutes of Health (5r01ca128803-05, ES002109)
- Ludwig Center at Harvard
- National Cancer Institute (R01-CA128803, CA14051, Koch Institute Support (core) Grant P30-CA14051, Grant P30-CA14051, P30CA014051, P30-CA-14051)
- National Institute of Environmental Health Sciences (ES-015818, P30ES002109, R56ES015818, R01ES015818)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
- Health Sciences › Medicine › Oncology › Metal complexes synthesis and properties
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- REV3, pol, translesion synthesis, cisplatin resistance, non-small cell lung cancer, lung adenocarcinoma, chemoresistance, secondary malignancies, tumor transplantation, adjuvant therapy, DNA polymerase
- MeSH terms
- Adenocarcinoma, Animals, Cisplatin, DNA-Directed DNA Polymerase, DNA-Binding Proteins, Drug Screening Assays, Antitumor, Lung Neoplasms, Neoplasm Transplantation, Tumor Suppressor Protein p53, Proto-Oncogene Proteins p21(ras), Drug Resistance, Neoplasm, Catalytic Domain, Cell Line, Tumor, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
